Digital therapists get stressed too, study finds
And when chatbots get stressed out, they are less likely to be useful in therapeutic settings with people. The bot’s anxiety ...
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Healio9h
Societies take stand against off-brand GLP-1s over safety concerns
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
OPKO and Entera partner to develop obesity pill
(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...
Fierce Biotech10h
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in ...
BioSpace20h
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...